A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)

NCT06484920 Phase 2 RECRUITING

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

Details

Lead sponsor	Rita Assi
Phase	Phase 2
Status	RECRUITING
Enrolment	24
Start date	2024-11-18
Completion	2029-09

Conditions

• Relapsed Hodgkin Lymphoma
• Refractory Hodgkin Lymphoma
• Relapsed Non-Hodgkin Lymphoma
• Refractory Non-Hodgkin Lymphoma
• B-cell Lymphoma

Interventions

• ATRA
• Pembrolizumab

Primary outcomes

• Incidence of Adverse Events — from start of treatment through 90 days safety follow-up visit
  Safety will be assess by the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Countries

United States